BREDININ TREATMENT IN CLINICAL KIDNEY ALLOGRAFTING
BREDININ TREATMENT IN CLINICAL KIDNEY ALLOGRAFTING
复制标题
临床同种异体肾移植中的布雷迪宁治疗
DOI：
10.1097/00007890-198408000-00005
复制
发表时间：
1984
期刊：
影响因子：
6.2
通讯作者：
Y. Aso
中科院分区：
文献类型：
--
作者：
A. Tajima;M. Hata;N. Ohta;Y. Ohtawara;K. Suzuki;Y. Aso
Bredinin，一种新的核苷类抗生素，从Eupenicillium brefeldianum中分离出来，和类固醇被用作免疫抑制剂，在31例肾移植患者中，17例接受了活体供体的移植物，14例来自尸体。活体供肾者移植肾1年存活率为100%，尸体供肾者移植肾1年存活率为69.2%。使用这些免疫抑制剂没有严重并发症。
Bredinin, a new nucleoside antibiotic isolated from Eupenicillium brefeldianum, and steroids were used as immunosuppressive agents in 31 renal transplant patients; 17 of them received grafts from living-related donors and 14 from cadavers. The one-year graft survival rates were 100% in renal recipients from living donors and 69.2% in cadaver kidney recipients. There was no serious complication from the use of these immunosuppressive agents.